BACKGROUND: Pharmacists play an increasing role in advising on treatment for minor illnesses such as influenza-like illness (ILI) or ear, nose, and throat (ENT) disorders. However, the profile of patients consulting pharmacists with these illnesses, the types of over-the-counter (OTC) medicines recommended by pharmacists, and the effectiveness of these treatments have not been studied.
OBJECTIVES: To describe the sociodemographic and clinical characteristics of patients recommended allopathic and/or homeopathic medicines for ILI or ENT disorders by pharmacists in France and to investigate the effectiveness of these treatments.
METHODS: A prospective, observational, multicenter study was carried out in randomly selected pharmacies across the 8 IDREM medical regions of France. Pharmacies that agreed to participate recruited male or female patients who responded to the following inclusion criteria: age ≥ 12 years presenting with the first symptoms of an ILI or ENT disorder that were present for less than 36 hours prior to the pharmacy visit. All medicines recorded in the study were recommended by the pharmacists. The following data were recorded at inclusion and after 3 days of treatment: the intensity of 13 symptoms, global symptom score, and disease impact on daily activities and sleep. Two groups of patients were compared: those recommended allopathic medicine only (AT group) and those recommended homeopathic medicine with or without allopathic medicine (HAT group). The number and severity of symptoms, change in global symptom score, and disease impact on daily activities and sleep were compared in the 2 treatment groups after 3 days of treatment. Independent predictors of recommendations for homeopathic medicine were identified by multifactorial logistic regression analysis.
RESULTS: A total of 242 pharmacies out of 4,809 (5.0%) contacted agreed to participate in the study, and 133 (2.8%) included at least 1 patient; 573 patients were analyzed (mean age: 42.5 ± 16.2 years; 61.9% female). Of these, 428 received allopathic medicines only (74.7%; AT group), and 145 (25.3%) received homeopathic medicines (HAT group) alone (9/145, 1.6%) or associated with allopathy (136/145, 23.7%). At inclusion, HAT patients were significantly younger (39.6 ± 14.8 vs. 43.4 ± 16.1 years; P < 0.05), had a higher mean number of symptoms (5.2 ± 2.5 vs. 4.4 ± 2.5; P < 0.01), and more severe symptoms (mean global symptom score: 24.3 ± 5.5 vs. 22.3 ± 5.8; P = 0.0019) than AT patients. After 3 days, the improvement in symptoms and disease impact on daily activities and sleep was comparable in both groups of patients.
• Homeopathic medicines may have a specific place among the OTC medicines recommended by pharmacists. Little is known about the sociodemographic and clinical profiles of patients who take homeopathic medicines or the effectiveness of the different treatments proposed by pharmacists for ILI or ENT disorders.
What is already known about this subject
• The study describes the sociodemographic and clinical profiles of patients with ILI and ENT disorders who consult pharmacists for treatment advice. Patients who took homeopathic medicine, either alone or combined with allopathy (HAT group), were significantly younger (P < 0.05) and had more severe symptoms than those who took allopathic medicine only (AT group).
• The change in global symptom score after 3 days of treatment was comparable in both groups even though symptoms were significantly more severe in HAT patients at inclusion (P < 0.0001). After pharmacist-recommended treatment, there was no significant difference between both groups in the impact of the disease on daily activities and sleep.
• Both groups of patients were satisfied with the advice and medicines recommended by their pharmacists (87.5% of patients were satisfied in the HAT group vs. 85.3% in the AT group; P = NS). Consulting a pharmacist offers more immediate access to treatment advice than waiting for a consultation with a general practitioner. W inter illnesses such as the common cold, influenzalike illness (ILI), and ear, nose, and throat (ENT) disorders are common reasons for people to consult their general practitioner (GP). Two large studies carried out in the United States in 2001-2002 and 2007 on approximately 1 million ambulatory care patients each reported that cough was the most frequent reason for a primary care visit (4.3% and 2.8% of visits, respectively) and acute upper respiratory tract infection (URTI) was the second most frequent illness diagnosed after hypertension. 1, 2 Antibiotics are widely misused in patients with colds and URTI, with more than one third (35.7%) of all patients with this diagnosis receiving an antibiotic prescription. 3 This high level of use of prescription drugs such as antibiotics leads to suboptimal care, unnecessarily high health care costs, 4, 5 and increasing levels of antibiotic resistance. 3, 6 As part of their training, pharmacists are taught how to identify illnesses for which they can advise patients and deliver medication directly, over-the-counter (OTC), without the need for a medical prescription. In the United States 7 and France, 8 pharmacists are involved in disease management programs and are the first providers of advice and OTC medications for winter illnesses such as colds, ENT disorders, and ILIs. Seeking advice directly from a pharmacist can result in a prevented GP visit, shortening waiting times for other patients, and may help reduce antibiotic misuse. Studies in pharmacy practices can be used to assess the outcomes of treatments recommended directly by pharmacists in terms of symptom relief and side effects. The number of visits to a physician for a given illness can be used to assess the outcome of nonprescription-based treatments. Effective treatments will result in fewer visits. Homeopathic medicines may have a specific place among the medicines recommended by pharmacists. A homeopathic medicine is defined as any medicinal product prepared from substances called homeopathic stocks in accordance with a homeopathic manufacturing procedure described by the European Pharmacopoeia or, in the absence thereof, by the pharmacopoeias currently used officially in the member states of Europe. A homeopathic medicinal product may contain a number of stocks.
9-11 A homoeopathic preparation is usually designated by the Latin name of the stock, followed by an indication of the degree of dilution.
Comparative effectiveness studies in pharmacies are useful to compare the different types of medicines recommended by pharmacists to patients. OTC drugs are medicines that can be sold directly to consumers without a medical prescription and are selected by regulatory agencies to ensure that they are safe and effective when used without a physician's care. Some drugs may be legally classified as OTC but may only be dispensed by a pharmacist after an assessment of the patient's needs and/or the provision of patient education. In France, some medicines are dispensed OTC by pharmacists, whereas others are behind the pharmacy counter. This means that they can only be dis- Little is known about the sociodemographic and clinical profiles of patients who are recommended homeopathic medicines for winter illnesses such as ILI or ENT disorders or the effectiveness of the different treatments recommended by pharmacists for these illnesses. The objectives of the present pharmaco-epidemiological study were to compare the sociodemographic and clinical profiles of patients recommended homeopathic medicine for ILI or ENT disorders by their pharmacists, either alone or in association with allopathy, with those recommended allopathic medicine only and to compare the effectiveness of the different medicines recommended by the pharmacists.
■■ Methods Study Design
This prospective, observational, multicenter study was carried out among a representative sample of randomly selected pharmacies in France over a 5-month period from November 2010 to March 2011, which included the entire winter season and its associated pathologies. The study was strictly observational, and pharmacists were free to offer therapeutic advice without any modifications to their usual management of patients. According to the study protocol, the pharmacists were asked to provide advice and recommend medication rather than to respond to a request for a specific medicine by a patient.
The study was carried out in accordance with the principles of good practice in the conduct of pharmaco-epidemiological studies as defined in the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) or International Society for Pharmacoepidemiology (ISPE) guidelines. Regulatory approval was obtained from the National Council of the Order of Pharmacists and ethical approval from the French data protection authority (Commission Nationale de l'Informatique et des Libertés).
Patients were informed about the study by letter and were told by the participating pharmacists that their responses would remain confidential. Patients were not remunerated for participation, but pharmacists received compensation fees. Neither the pharmacists nor the patients were aware of the study sponsor (Laboratoires Boiron).
Recruitment of Pharmacies
Pharmacies were randomly selected from the national register of pharmacies in order to ensure representativity of pharmacies across France. An initial sample of 1,000 pharmacies was selected with stratification into the 8 IDREM medical regions, 14 assuming an anticipated participation rate of 10%-15%. A second sample of pharmacies was selected with regional stratification to ensure a sufficient number of participating pharmacies. Each IDREM medical region corresponds to a well-defined number of departments.
14 The target number of pharmacies was an estimate because it was not known what symptoms the patients would declare or which medicines would be recommended by the pharmacists. There are currently no guidelines for the definition of ILI although a number of definitions have been proposed. 15, 16 All pharmacies were contacted by mail or by telephone, and those agreeing to participate were sent a kit containing all of the study documents. In the case of an insufficient response rate, pharmacies would be contacted directly by mail or by telephone. A total of 4,809 pharmacies were contacted.
All pharmacist investigators were briefed on the study and on all the study documents. All study documents were in French.
During the study, the pharmacists were responsible for administering the survey, completing the observation files, and asking the patients to fill in a self-assessment questionnaire in private. Pharmacies that included at least 1 patient were listed as active pharmacies.
Selection of Patients
Participating pharmacies were asked to recruit the first 10 patients, male or female, who responded to the following inclusion criteria: age ≥ 12 years, presenting with the first symptoms of an ILI or ENT disorder that were present for less than 36 hours prior to the pharmacy visit, receiving a treatment recommendation directly from the pharmacist, agreeing to participate in the study, and agreeing (or whose parents agreed if the subject was < 18-years) to be recontacted by telephone 3 days later. Patients aged ≥ 12 years were included in this study, as they are in many other studies, since persons in this age group are considered to present the same symptoms as adults. 17, 18 In addition, it was considered that children between 12 and 18 years were capable of responding to the questions asked. In our study, the parents helped the children complete the questionnaires if they were having difficulty.
The exclusion criteria were as follows: patients requesting a specific medication themselves, refusal to participate, language barrier (i.e., patient unable to read the information letter and/ or respond to the paper questionnaire or interview in French), patient presenting a medical prescription, and major psychiatric disorder.
The sample size considerations for pharmacies (n = 130) and patients (n = 10 per pharmacy) were based on the minimum number of subjects required to identify the factors influencing patient satisfaction according to the studies conducted by Concato et al. (1995) 19 and Ferley et al. (1987) .
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Data Collected
Quantitative data (age) and qualitative data (sex, socioprofessional status, smoking history, preexisting chronic respiratory disorders, influenza vaccination, and medications taken prior to visiting the pharmacist) were recorded for each patient at inclusion. Pharmacists were provided with an observation file
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and were asked to record the following information for each patient at inclusion: the clinical symptoms of the ILI or ENT disorder, the medicines (homeopathic and allopathic) recommended and accepted by the patient, any self-medication taken by the patient before visiting the pharmacist, and any longterm treatments taken. At inclusion, the patients were also asked to fill in a selfassessment questionnaire with questions relating to their socioprofessional status, intensity of symptoms, and impact of those symptoms on daily activities and sleep. The patients were also asked if they had either of the following comorbid illnesses: chronic or allergic respiratory disorders. This questionnaire was completed in a private area of the pharmacy.
The following 13 symptoms were assessed on a 4-point scale: nasal discharge, sore throat, cough, exhaustion/fatigue, headache, muscular aches/pains, blocked nose, shivering, fever, sneezing, hoarseness/broken voice, vomiting/nausea, and diarrhea, based on whether they were absent (= 1), mild (= 2), moderate (= 3), or severe (= 4). A global symptom score was determined based on the sum of the individual scores (range: 13-52). This symptom scale has not been validated previously as there is an absence of consensus on the definition of ILI symptoms.
15, 16 Many scales have been used and validated for influenza but not for ILI; for example, the 8-symptom scale described by Ha et al. (2012) . 21 The impact of the disease was assessed by asking 2 questions on daily activities and sleep using a 7-point Likert scale: 1 = not at all affected to 7 = extremely affected.
All participating patients were contacted by a clinical research associate 3 days after their initial visit to the pharmacist to carry out a follow-up survey. This final questionnaire included questions on the intensity of symptoms, any concomitant respiratory pathologies, adherence to the recommended medicines, use of any other medicines, impact of the illness on daily activities and sleep, and satisfaction with the advice they had received. Patient satisfaction with the pharmacists' advice was assessed on a 4-point Likert scale ranging from 1 = dissatisfied to 4 = extremely satisfied.
Statistical Analyses
For the analysis of the results, the study population was divided into 2 groups according to the types of medicines recommended by the pharmacists: the HAT group, which included patients who were recommended homeopathic medicine, with or without allopathic medicine, and the AT group, which included patients who were recommended allopathic medicine only.
Descriptive statistics included means, standard deviations, medians, and quartiles for continuous variables and numbers and percentages for categorical variables.
Patients in the HAT and AT groups were compared for age, sex, socioprofessional status, smoking history, preexisting chronic respiratory disorders, influenza vaccination, and medications taken prior to visiting the pharmacist. Intergroup comparisons were carried out using the Student's t-test for quantitative variables and chi-square test for qualitative variables. Multifactorial logistic regression analysis was performed on any factors with a significance level of ≤ 0.2 in order to identify independent predictors of proposal of homeopathic medicine alone or in association with allopathic medicine, along with their odds ratios (ORs) and 95% confidence intervals (CIs). Clinical determinants that were pertinent were integrated into the statistical model. The variables included in the final logistic regression model (after stepwise selection) were age, sex, intensity of the impact of the illness, and symptoms at inclusion.
The evaluation of clinical symptoms and their impact on daily activities and sleep were assessed using the Wilcoxon signed-rank or McNemar test for qualitative variables and repeated measure analysis of variance for quantitative variables. For all analyses, the limit of significance was set at P < 0.05. All statistical analyses were conducted using SAS version 9.1.3 (SAS Institute, Inc., Cary, NC).
■■ Results
Study Population
A total of 242 pharmacies of the 4,809 (5.0%) contacted agreed to participate in the study, and 133 (2.8%) included at least 1 patient; this was lower than the anticipated 10%-15% participation rate. The geographical distribution of the 133 active pharmacies reflected the overall distribution of pharmacies in the national register with the exception of the Parisian region, which was underrepresented (9.8% in our study vs. 18.5% in the register) and the Centre-East region, which was overrepresented (18.8% in our study vs. 11.7% in the register).
A total of 573 patients were included in the final analysis (mean age: 42.5 ± 16.2 years, range: 12-84; 61.9% female). Of these patients, 428 (74.7%) received allopathic medicine only (AT group), and 145 (25.3%) received homeopathic medicine (HAT group), either alone (9/145, 1.6%) or associated with allopathic medicine (136/145, 23.7%).
The 428 patients who received allopathic medicine only (AT group) were included by 105 pharmacists, and the 145 HAT patients were included by 75 pharmacists. Thus, there was a wide representation of pharmacies in the 2 treatment groups. Some pharmacies among the 133 active pharmacies included patients in the 2 groups.
Comparison of the Sociodemographic and Clinical Characteristics of HAT Patients Versus AT Patients
Sociodemographic Characteristics. The sociodemographic characteristics of the 2 groups of patients are shown in Table 2 . There was no significant difference between the groups in terms of sex, socioprofessional status, geographic location of the pharmacy, or factors that may favor the development or severity of ILI or ENT disorders such as smoking or the presence of an underlying chronic respiratory disorder (asthma,
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Management of Influenza-like Illnesses or Ear, Nose, and Throat Disorders by Pharmacists chronic bronchitis, or allergic rhinitis). The groups were also comparable in terms of influenza vaccination status and whether the patients had taken any medication before seeking the advice of a pharmacist. However, significantly more patients in the HAT group had taken paracetamol before consulting the pharmacist than in the AT group (67.8% vs. 49.6%, respectively; P < 0.05).
The only other significant difference between the groups was age: patients in the HAT group were significantly younger than those in the AT group (39.6 vs. 43.4 years; P < 0.05). The difference in age distribution between the groups was mainly due to a greater proportion of patients aged ≥ 60 years in the group receiving AT only (20.3% vs. 11.0%, respectively; Table 2 ).
Clinical Characteristics at Inclusion. The clinical symptoms in the 2 groups of patients at inclusion differed significantly (Figure 1) . Patients in the HAT group presented more often with shivering (53.1% vs. 31.8%; P < 0.0001), muscular aches/ pains (49.0% vs. 35.3%; P < 0.01), exhaustion/fatigue (54.5% vs. 41.4%; P < 0.01), hoarseness/broken voice (31.0% vs. 21.7%; P < 0.05), and sneezing (38.6% vs. 26.4%; P < 0.01). The results for fever were at the limit of statistical significance (40.7% vs. 32.0%; P = 0.0569).
In contrast, there was no significant difference in the frequency of headaches (45.5% vs. 42.3%; P = 0.50), cough (51.0% vs. 48.4%; P = 0.58), sore throat (51.0% vs. 55.8%; P = 0.32), nasal discharge (57.2% vs. 56.1%; P = 0.81), blocked nose (36.6% vs. 38.6%; P = 0.67), nausea/vomiting (4.1% vs. 3.3%; P = 0.62), and diarrhea (2.1% vs. 2.3%; P = 1.0000).
The mean number of symptoms declared premedication was significantly higher in patients recommended HAT than in those given AT (5.2 ± 2.5 vs. 4.4 ± 2.5, respectively; P < 0.01). The 
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FIGURE 1
Percentage of Patients Declaring Each Symptom to the Pharmacist and Duration of Symptoms in Patients Treated with Allopathy Only and Those Given
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Management of Influenza-like Illnesses or Ear, Nose, and Throat Disorders by Pharmacists and were dispensed to 52.1% of patients in the AT group versus 77.9% in the HAT group. In contrast, medicines containing drug combinations (medications with several active ingredients for the treatment of multiple symptoms, e.g., paracetamol + pseudo-ephedrine) were also commonly dispensed in the AT group (42.8% vs. 17.9% in the HAT group). Drops, throat and nasal sprays, and throat lozenges were dispensed to 80% of subjects in the AT group and to 59.3% in the HAT group. Vitamins and trace elements were more often dispensed to patients in the HAT group than to AT patients (27.6% vs. 15%).
The most common homeopathic medicine recommended by pharmacists was Anas barbariae 200C (Oscillococcinum, Boiron Laboratories, France). This was recommended to 82 patients (14.3%), or more than half (56.6%) of those who received homeopathic medicines. A homeopathic combination of several stocks (L52, Lehning Laboratories, France), a medicine used for flu-like states, was recommended to 17 patients (2.9%), or 11.7% of those who received homeopathic medicines. A homeopathic combination of several stocks (STODAL, Boiron Laboratories, France), a medicine for cough, was recommended to 17 patients (2.9%), or 11.7% of those who received homeopathic medicines. The medicines recommended by pharmacists were taken up to day 3 by 77.8% and 77.0% of patients in the HAT and AT groups, respectively (P = NS). Among the patients who stopped medication prematurely, the main reasons for discontinuation were a decrease in intensity of symptoms (28.1% of HAT vs. 40.2% of AT patients) or the disappearance of symptoms (31.3% vs. 25.8%, respectively). A small proportion of patients in each group (HAT 3.1% vs. AT 1.0%, respectively) experienced an adverse event (AE) during treatment. There was no common AE among the patients, and no AE was considered to be attributable to the recommended medications.
Comparison of Symptom Improvement and Change in Impact of Symptoms on Daily Life
Improvement of the 13 symptoms after 3 days of treatment was comparable in both groups (Figure 2 ) regardless of whether the symptoms were more severe or were similar in intensity at inclusion. The final global symptom score after 3 days of treatment was comparable in both groups even though the symptoms were significantly more severe in the HAT group at inclusion (P < 0.0001).
At the initial visit to the pharmacist, the impact of the illness on daily activities and sleep was more marked in the HAT group than in AT patients. This was related to the initial symptoms, which were more severe in the HAT group. After treatment, there was no significant difference between the groups in the extent to which the illness impacted daily activities and sleep (Figure 3) . Both groups of patients were satisfied with the advice and medicines that were recommended by their pharmacists (87.5% of patients were satisfied in the HAT group vs. 85.3% in the AT group; P = NS). global score for symptom intensity was also significantly higher in HAT patients at inclusion (24.3 ± 5.5 vs. 22.3 ± 5.8, respectively; P = 0.0019). There was no significant difference in the duration of symptoms prior to visiting the pharmacist (Figure 1) . The need to consult a GP for aggravation of symptoms was also similar in both groups (25.0% HAT vs. 23.7% AT).
Logistic regression showed that age < 18 years (patients aged 12-18 years vs. ≥ 60 years [OR = 3.649; 95% CI = 1.274-10.452]), shivering at inclusion (OR = 2.048; 95% CI = 1.341-3.130), and sneezing at inclusion (OR = 1.771; 95% CI = 1.111-2.825) appeared to play a role in determining whether therapeutic advice favored treatment including a homeopathic medicine (Table 3) .
Management of Symptoms of ILI and ENT Disorders
Pharmacists recommended a mean of 2.4 ± 1.1 medicines/ patient in the AT group and 3.4 ± 1.1 medicines/patient in the HAT group, with a mean of 1.2 ± 0.5 homeopathic medicines/ patient (corresponding to an average proportion of 38.9% (± 19.8) homeopathic medicines/patient). Analgesics and antipyretics were the most commonly recommended medicines 
■■ Discussion
Homeopathic medicine, with or without allopathic medicine, appears to be effective at alleviating the symptoms of ILI or ENT disorders. Multiple regression analysis of the sociodemographic characteristics of patients who were recommended homeopathic medicines showed that they were significantly younger and had more severe symptoms at inclusion than those recommended allopathic medicines only. These results are concordant with those published in the literature. Few epidemiological surveys similar to ours have been carried out among pharmacies in France. However, a computerassisted telephone interview survey carried out in Germany on adult allergy patients using complementary and alternative medicine (CAM) including homeopathy (35.3%) showed that CAM users tended to be younger, better educated, and more aware of the side effects of allopathic medicines compared with nonusers. 22 Younger age and a higher level of education were also reported among homeopathy users in several other studies. [23] [24] [25] Several studies have also reported that users of CAM are more likely to be female. 23, 25 Although the difference in the sex ratio between the 2 groups in our study was not statistically significant, there was nevertheless a trend toward a greater proportion of women using homeopathy (60.5% female in the AT group vs. 66.0% female in the HAT group; P = NS). Patients who were treated with homeopathic medicines reported more severe symptoms at inclusion than those who took allopathic medicine only. These patients also reported more symptoms at inclusion than those in the AT group (5.2 ± 2.5 vs. 4.4 ± 2.5, respectively; P < 0.01). This is in agreement with previous findings in a Norwegian study that reported lower perceived global health among patients consulting homeopaths. 26 It is noteworthy that patients in our HAT group had more severe symptoms at inclusion than those in the AT group and that more patients in the HAT group had selfmedicated with paracetamol before consulting the pharmacist.
Of the 6 symptoms that were more severe in HAT patients at inclusion, fever had disappeared at day 3 in more patients in the HAT group, and shivering, muscular aches/pains, exhaustion/fatigue, sneezing and hoarseness/broken voice had all improved. These results are in line with studies in the literature that demonstrate the effectiveness of homeopathic medicine compared with allopathy or placebo in patients with acute 20, [27] [28] [29] [30] or chronic 31−35 diseases of the ear, sinuses, and upper airways. Patients who used homeopathic medicines in our study did not have a reduced chance of recovery at 3 days and presented with improved symptoms without suffering more complications or side effects than patients taking allopathic medicines only.
Concerning the HAT group, most patients took homeopathic medicine in combination with allopathic medicine (136/145, 93.7%), and few took homeopathic medicine alone. It is not known whether the pharmacists recommended homeopathic medicine to some patients only or whether some patients refused homeopathic treatment. However, the association of homeopathic with allopathic medicines is often found in other studies, for example, the study of Vincent et al. (2012) , where 41.7% of patients with ILI were prescribed both homeopathic and allopathic medicines. 36 In this study, patients treated for ILI with homeopathic medicines only were more satisfied with their treatment than other patients. 36 In both of our groups of patients, analgesics and antipyretics were the most commonly recommended types of medicine. Medicines containing drug combinations were more commonly dispensed in the AT group, whereas vitamins and trace elements were more often dispensed to HAT patients. Some of these drug combinations could contain pseudoephedrine, which is associated with various side effects. The most frequently recommended homeopathic medicine was Anas barbariae 200C (Oscillococcinum). Two previous studies reported that Anas barbariae 200C (Oscillococcinum) was effective in ILI and resulted in a significantly greater decrease in symptoms after 48 hours of treatment and a shorter illness duration compared with placebo, with a significantly greater proportion of patients considering that homeopathy had been effective. 20, 27 No data on efficacy are available in the literature for homeopathic combinations of several stocks (L52 or STODAL), but in a comparative study of homeopathy versus conventional treatment in the primary care setting, Haidvogl et al. (2007) reported that homeopathic treatment for acute respiratory and ear complaints was not inferior to conventional treatment. 29 A total of 62 different homeopathic medicines were prescribed, with Belladonna (13.3%) and Pulsatilla (10.6%) the most frequently given to children and Hepar sulphuris (9.7%) and Belladonna (8.3%) the most frequent for adults. 29 The results of our observational, multicenter study suggest that pharmacists in France play an important role in advising patients and recommending medicines for minor illnesses such as ILI and ENT disorders. Greater involvement of pharmacists in primary care has also been reported in the United States. Pharmacist-provided medication therapy management interventions evolved between January 2000 and December 2006 from the provision of patient education on acute medications to consultation-type services for chronic medications. 37 In our study, the medications recommended by pharmacists, either allopathic, homeopathic, or both, appeared to be effective at reducing the main symptoms of ILI or ENT disorders. Consulting a pharmacist directly has the advantage of more rapid access to treatment advice and eliminates unnecessary GP consultations. Care strategies involving homeopathic medicines and nonprescription-based drugs are associated with less antibiotic use and lower health care costs than prescriptionbased strategies.
4,5,37
Limitations
The results of this observational study are limited by the fact that few patients in the HAT group took homeopathic medicine only (9/145, 1.6%); therefore, the effectiveness of homeopathic medicines alone in ILI and ENT disorders could not be assessed. Furthermore, there was no control group that took no medication to determine whether the illness was self-limiting and whether the improvement in symptoms was not medication dependent. A properly designed, large-scale, controlled clinical trial of homeopathic medicine in patients with winter illnesses will help to determine the efficacy of such treatments. Such a study should take into consideration the problems in homeopathic trial design frequently cited in the literature. 31, [38] [39] [40] Although it would have been interesting to do, it was not an objective of this study to look at whether pharmacists' recommendations for allopathic or homeopathic medicines varied between the different regions of France. However, the French territory is not huge and our pharmacies were homogeneously distributed across the country. It is important to note that although the recommendations for medication came from the pharmacists, we were not able to control whether patients' views on a type of treatment influenced the medications received.
■■ Conclusions
Pharmacists in France may recommend homeopathic medicine for winter illnesses such as ENT disorders and ILI, with or without allopathic medicine. In this study, homeopathic medicine was recommended to younger patients with more severe symptoms and did not seem to be disadvantageous in terms of efficacy. The medicines recommended by the pharmacists appeared to be effective at reducing the main symptoms of ILI and ENT disorders at 3 days.
Although payers in our managed health care system (managed care pharmacists) are not directly concerned with patient outcomes from treatments that do not require physician visits or other forms of insurance coverage, this study nonetheless reiterates the important role of pharmacists in the management of winter illnesses. The pharmacist has an important role to play as a health professional of first recourse to avoid an automatic medical consultation. Expansion of this role to other minor illnesses will help decrease GP waiting lists and antibiotic misuse/overuse.
